

David F Penson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3631174/david-f-penson-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

440 papers	22,481 citations	68 h-index	142 g-index
685 ext. papers	26,119 ext. citations	3.2 avg, IF	6.69 L-index

#	Paper	IF	Citations
440	Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.. <i>Journal of Urology</i> , 2022 , 101097JU00000000000002370	2.5	1
439	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021 , 159, 237-246	7.5	2
438	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 2559-2565	4	3
437	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 769-779	2.5	11
436	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 761-768	2.5	6
435	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 779	2.5	1
434	Editorial Comment. <i>Journal of Urology</i> , 2021 , 205, 1646	2.5	
433	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021 , 4, 396-404	6.7	10
432	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. <i>Urologic Oncology, Seminars and Original Investigations</i> , 2021 , 49, 51-56	2.8	
431	Benchmarking patient satisfaction scores in a colorectal patient population. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 35, 309-316	5.2	
430	A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 305-311	3.6	2
429	The Impact of Hospital Volume on Short-term and Long-term Outcomes for Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2021 , 147, 135-142	1.6	2
428	Racial disparities in mortality for patients with prostate cancer after radical prostatectomy. <i>Cancer</i> , 2021 , 127, 1517-1528	6.4	5
427	The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2021 , 15, 315-317	2.9	0
426	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 84-84	2.2	0
425	Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. <i>Cancer</i> , 2021 , 127, 1912-1925	6.4	1
424	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 134-143	7.3	71

423	Out-of-pocket costs for commercially insured patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 797-805	2.8	0
422	Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021 , 17, 420-425	1.2	0
421	What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 1949-1959	2.4	4
420	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2197-2206	59.2	114
419	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020 , 126, 2935-2937	6.4	
418	Patient expectations of benefit from systemic treatments for metastatic prostate cancer. <i>Cancer Medicine</i> , 2020 , 9, 980-987	4.8	2
417	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 517-526	6.2	48
416	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. <i>European Urology</i> , 2020 , 78, 248-255	10.2	4
415	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 149-163	27.4	57
414	Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. <i>Journal of Urology</i> , 2020 , 204, 1236-1241	2.5	4
413	National Variation in Elective Colon Resection for Diverticular Disease. <i>Annals of Surgery</i> , 2020 , 275,	7.8	3
412	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020 , 126, 583-592	6.4	7
411	Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. <i>European Urology Focus</i> , 2020 , 6, 205-207	5.1	2
410	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 930.e23-930.e32	2.8	1
409	Patient-Reported Outcome Measures in Colon and Rectal Surgery: A Systematic Review and Quality Assessment. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 1156-1167	3.1	5
408	MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 740-746.e4	2.4	2
407	Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. <i>Drug Safety</i> , 2020 , 43, 23-33	5.1	2
406	Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. <i>American Journal of Epidemiology</i> , 2019 , 188, 928-939	3.8	7

405	Modeling economic and epidemiological impact of voluntary medical male circumcision among men who have sex with men in Beijing, China. <i>International Journal of STD and AIDS</i> , 2019 , 30, 630-638	1.4	5
404	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 556-569	21.7	56
403	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019 , 125, 3853-3863	6.4	3
402	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 4172-4180	6.4	34
401	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. <i>Medical Decision Making</i> , 2019 , 39, 962-974	2.5	5
400	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5035-5035	2.2	4
399	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 479-505	7.3	562
398	Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 236-236	2.2	
397	Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5098-TPS5098	2.2	
396	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 972	2.5	
395	A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). <i>Journal of Urology</i> , 2019 , 201, 682-692	2.5	38
394	Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. <i>Journal of Urology</i> , 2019 , 201, 470-477	2.5	26
393	Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?. <i>Journal of Urology</i> , 2019 , 202, 1150-1158	2.5	7
392	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. <i>Future Oncology</i> , 2018 , 14, 527-536	3.6	
391	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. <i>European Urology</i> , 2018 , 74, 26-33	10.2	21
390	Re: Narrow Networks on the Health Insurance Marketplaces: Prevalence, Pricing, and the Cost of Network Breadth. <i>Journal of Urology</i> , 2018 , 199, 883-884	2.5	
389	Re: Strategies for Identifying and Closing the Gender Salary Gap in Surgery. <i>Journal of Urology</i> , 2018 , 199, 332-334	2.5	
388	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. <i>Journal of Urology</i> , 2018 , 199, 1202-1209	2.5	29

387	Considering quantity and quality of life in metastatic castration-naïve prostate cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 153-154	21.7	1
386	Editorial Comment. <i>Journal of Urology</i> , 2018 , 199, 1232	2.5	
385	Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening. <i>JAMA Internal Medicine</i> , 2018 , 178, 648-654	11.5	20
384	Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer. <i>Journal of Cancer Education</i> , 2018 , 33, 325-331	1.8	10
383	Surgeon Participation in Early Accountable Care Organizations. <i>Annals of Surgery</i> , 2018 , 267, 401-407	7.8	25
382	Decision-making processes among men with low-risk prostate cancer: A survey study. <i>Psycho-Oncology</i> , 2018 , 27, 325-332	3.9	12
381	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018 , 73, e98-e99	10.2	2
380	Hospital-Physician Consolidation Accelerated In The Past Decade In Cardiology, Oncology. <i>Health Affairs</i> , 2018 , 37, 1123-1127	7	48
379	Clinical trials in urology 2018 , 19-24		
378	Fibromyxoid Nephrogenic Adenoma in the Ureter. <i>Journal of Endourology Case Reports</i> , 2018 , 4, 97-99	0.3	5
377	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018 , 168, 1-9	8	25
376	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 116-126	4	5
375	Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5010-5010	2.2	4
374	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17018-e17018	2.2	1
373	Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 228-228	2.2	
372	Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 234-234	2.2	
371	Do accountable care organizations affect race mediated differences in cancer screening?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 131-131	2.2	
370	Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5043-5043	2.2	1

369	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5041-5041	2.2	
368	Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16513-e16513	2.2	
367	Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer. <i>Clinical Oncology and Research</i> , 2018 , 1, 2-7	0.9	1
366	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of The Mid 1990s for Localized Prostate Cancer. <i>Urology Practice</i> , 2018 , 5, 471-479	0.8	1
365	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 937-941	2.2	3
364	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
363	The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening. <i>Cancer</i> , 2018 , 124, 4366-4373	6.4	5
362	Racial variation in receipt of quality radiation therapy for prostate cancer. <i>Cancer Causes and Control</i> , 2018 , 29, 895-899	2.8	5
361	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <i>BMC Urology</i> , 2018 , 18, 77	2.2	1
360	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. <i>Practical Radiation Oncology</i> , 2018 , 8, 307-316	2.8	5
359	The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 51-58	2.8	14
358	Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 401-402	2.5	
357	Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 702-704	2.5	
356	Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. <i>Journal of Urology</i> , 2017 , 197, 703	2.5	
355	Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 703-704	2.5	
354	Urinary retention and catheter use among U.S. female Medicare beneficiaries: Prevalence and risk factors. <i>Neurourology and Urodynamics</i> , 2017 , 36, 2101-2108	2.3	7
353	Cost-effective management of pelvic fracture urethral injuries. <i>World Journal of Urology</i> , 2017 , 35, 1617-1623	4.623	6
352	TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 286-293	2.8	13

351	Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort. <i>Journal of Urology</i> , 2017 , 198, 104-106	2.5	
350	Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. <i>Journal of Urology</i> , 2017 , 198, 104-105	2.5	
349	Patient-Reported Outcome Measures in Upper Airway-Related Dyspnea: A Systematic Review. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 824-831	3.9	8
348	Recent Changes in Prostate Cancer Screening Practices and Epidemiology. <i>Journal of Urology</i> , 2017 , 198, 1230-1240	2.5	63
347	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. <i>Urology</i> , 2017 , 103, 173-178	1.6	11
346	Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. <i>European Urology</i> , 2017 , 72, 712-735	10.2	56
345	Re: Projecting the Urology Workforce over the Next 20 Years. <i>Journal of Urology</i> , 2017 , 197, 1339	2.5	
344	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1126-1140	27.4	177
343	Re: Impact of Hair Removal on Surgical Site Infection Rates: A Prospective Randomized Noninferiority Trial. <i>Journal of Urology</i> , 2017 , 197, 1462-1463	2.5	1
342	Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. <i>Journal of Urology</i> , 2017 , 197, 1251-1257	2.5	14
341	Voice-Related Patient-Reported Outcome Measures: A Systematic Review of Instrument Development and Validation. <i>Journal of Speech, Language, and Hearing Research</i> , 2017 , 60, 62-88	2.8	43
340	Reply to I.E. Haines. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1626-1627	2.2	
339	Reply to M.A.N. Bndur et al and J. Michels. <i>Journal of Clinical Oncology</i> , 2017 , 35, 123	2.2	1
338	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2306-2314	2.2	47
337	Physicians' perspectives on the informational needs of low-risk prostate cancer patients. <i>Health Education Research</i> , 2017 , 32, 134-152	1.8	5
336	Re: Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. <i>Journal of Urology</i> , 2017 , 198, 248	2.5	
335	Re: Preoperative Frailty Predicts Postoperative Complications and Mortality in Urology Patients. <i>Journal of Urology</i> , 2017 , 198, 474	2.5	
334	Re: Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality after Radical Cystectomy. <i>Journal of Urology</i> , 2017 , 198, 474-475	2.5	

333	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. <i>Journal of Urology</i> , 2017 , 198, 744-745	2.5	
332	Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer. <i>Journal of Urology</i> , 2017 , 198, 1033-1038	2.5	14
331	Re: A Comparison of Web-Based versus Print-Based Decision Aids for Prostate Cancer Screening: Participants' Evaluation and Utilization. <i>Journal of Urology</i> , 2017 , 197, 154	2.5	
330	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. <i>European Urology</i> , 2017 , 72, 307-314	10.2	11
329	Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. <i>JAMA Surgery</i> , 2017 , 152, 27-34	5.4	16
328	Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 153-154	2.5	
327	An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival. <i>Journal of Urology</i> , 2017 , 197, 37-43	2.5	3
326	Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 2017 , 233-241		
325	Patient expectations from systemic treatment of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 218-218	2.2	1
324	Therapeutic Ultrasound and Prostate Cancer. <i>Seminars in Interventional Radiology</i> , 2017 , 34, 187-200	1.6	10
323	Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 216-216	2.2	
322	The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 207-207	2.2	
321	Validation of the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer (CRPC): Data from TRUMPET.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 256-256	2.2	
320	Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16542-e16542	2.2	1
319	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. <i>Journal of Urology</i> , 2016 , 195, 321-9	2.5	42
318	Patient-Reported Outcome Measures Related to Laryngopharyngeal Reflux: A Systematic Review of Instrument Development and Validation. <i>Otolaryngology - Head and Neck Surgery</i> , 2016 , 155, 923-935	5.5	35
317	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. <i>Future Oncology</i> , 2016 , 12, 2689-2699	3.6	4
316	Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. <i>Journal of Urology</i> , 2016 , 195, 1720	2.5	

3 ¹⁵	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. <i>Journal of Urology</i> , 2016 , 196, 1030-5	2.5	14
3 ¹⁴	Re: Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. <i>Journal of Urology</i> , 2016 , 195, 353-4	2.5	1
3 ¹³	Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Urology</i> , 2016 , 196, 352-4	2.5	2
3 ¹²	Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. <i>Circulation</i> , 2016 , 133, 537-41	16.7	72
3 ¹¹	Successful external validation of a model to predict other cause mortality in localized prostate cancer. <i>BMC Medicine</i> , 2016 , 14, 25	11.4	15
3 ¹⁰	Prostate Cancer Registries: Current Status and Future Directions. <i>European Urology</i> , 2016 , 69, 998-1012	10.2	39
3 ⁰⁹	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2098-106	2.2	213
3 ⁰⁸	Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	10
3 ⁰⁷	Anticipating the Unintended Consequences of Closing the Door on Physician Self-Referral. <i>Journal of Urology</i> , 2016 , 196, 444-50	2.5	3
3 ⁰⁶	Re: Changes in Burnout and Satisfaction with Work-Life Balance in Physicians and the General US Working Population between 2011 and 2014. <i>Journal of Urology</i> , 2016 , 195, 1568	2.5	4
3 ⁰⁵	Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2016 , 195, 353	2.5	2
3 ⁰⁴	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 320-320	2.2	
3 ⁰³	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 241-241 ^{2.2}		
3 ⁰²	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16503-e16503 ^{2.2}		
3 ⁰¹	Checklist to operationalize measurement characteristics of patient-reported outcome measures. <i>Systematic Reviews</i> , 2016 , 5, 129	3	50
3 ⁰⁰	Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications. <i>Medical Care</i> , 2016 , 54, 738-44	3.1	8
2 ⁹⁹	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. <i>Medical Care</i> , 2016 , 54, e47-54	3.1	42
2 ⁹⁸	Renal cell cancer histological subtype distribution differs by race and sex. <i>BJU International</i> , 2016 , 117, 260-5	5.6	73

297	Prostate Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 19-30	7.3	473
296	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>Journal of Urology</i> , 2016 , 196, 105-6	2.5	2
295	Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. <i>Journal of Urology</i> , 2016 , 195, 928-9	2.5	
294	Re: Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. <i>Journal of Urology</i> , 2016 , 196, 105	2.5	2
293	Re: Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries. <i>Journal of Urology</i> , 2016 , 196, 1504	2.5	
292	Editorial Comment. <i>Urology</i> , 2016 , 95, 3-4	1.6	2
291	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. <i>Journal of Health Communication</i> , 2016 , 21, 99-104	2.5	37
290	Effect of injection augmentation on need for framework surgery in unilateral vocal fold paralysis. <i>Laryngoscope</i> , 2016 , 126, 128-34	3.6	26
289	Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries. <i>Journal of General Internal Medicine</i> , 2015 , 30, 440-7	4	25
288	Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsement. <i>Journal of Oncology Practice</i> , 2015 , 11, e445-9	3.1	18
287	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. <i>European Urology</i> , 2015 , 67, 1019-1025	10.2	12
286	Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. <i>Journal of Urology</i> , 2015 , 194, 1587-93	2.5	90
285	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015 , 68, 891-8	10.2	59
284	Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1078-85	2.2	78
283	Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. <i>Journal of General Internal Medicine</i> , 2015 , 30, 924-34	4	16
282	Nationwide trends in mastectomy for early-stage breast cancer. <i>JAMA Surgery</i> , 2015 , 150, 9-16	5.4	385
281	Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. <i>Circulation</i> , 2015 , 132, e218-20	16.7	10
280	Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. <i>Journal of Urology</i> , 2015 , 193, 1226-31	2.5	23

279	Re: Exploring the Burden of Inpatient Readmissions after Major Cancer Surgery. <i>Journal of Urology</i> , 2015 , 194, 1068	2.5	
278	Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. <i>Urology</i> , 2015 , 85, 92-100	1.6	24
277	Re: Effect of insurance expansion on utilization of inpatient surgery. <i>Journal of Urology</i> , 2015 , 193, 256	2.5	1
276	Re: Procedures take less time at ambulatory surgery centers, keeping costs down and ability to meet demand up. <i>Journal of Urology</i> , 2015 , 193, 257-8	2.5	
275	Urinary diversion: how experts divert. <i>Urology</i> , 2015 , 85, 233-8	1.6	49
274	Adverse effects of androgen deprivation therapy and strategies to mitigate them. <i>European Urology</i> , 2015 , 67, 825-36	10.2	394
273	Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. <i>Urology Practice</i> , 2015 , 2, 190-198	0.8	4
272	MP27-11 DISTINCT SIDE EFFECT PROFILES AFTER CONTEMPORARY TREATMENT OF LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2015 , 193,	2.5	1
271	Re: Association of Hospital Participation in a Quality Reporting Program with Surgical Outcomes and Expenditures for Medicare Beneficiaries. <i>Journal of Urology</i> , 2015 , 194, 1068-9	2.5	
270	Trends in urodynamics in U.S. female medicare beneficiaries, 2000-2010. <i>Neurourology and Urodynamics</i> , 2015 , 34, 420-3	2.3	6
269	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen. <i>BJU International</i> , 2015 , 116, 65-71	5.6	32
268	Survivorship and improving quality of life in men with prostate cancer. <i>European Urology</i> , 2015 , 68, 374-83	10.2	65
267	Re: Long-term effect of hospital pay for performance on mortality in England. <i>Journal of Urology</i> , 2015 , 193, 953-4	2.5	
266	Increasing use of observation among men at low risk for prostate cancer mortality. <i>Journal of Urology</i> , 2015 , 193, 801-6	2.5	39
265	Re: Ultrasonography versus computed tomography for suspected nephrolithiasis. <i>Journal of Urology</i> , 2015 , 193, 899	2.5	
264	A 22 Gene-expression Assay, Decipher [®] (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. <i>PLOS Currents</i> , 2015 , 7,		19
263	Creation of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 282-282	2.2	
262	Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16088-e16088	2.2	

261	Urinary functional outcomes in female neobladder patients. <i>World Journal of Urology</i> , 2014 , 32, 221-8	4	32
260	Overdiagnosis and overtreatment of prostate cancer. <i>European Urology</i> , 2014 , 65, 1046-55	10.2	528
259	Re: Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. <i>Journal of Urology</i> , 2014 , 192, 1421-1423	2.5	1
258	The hidden agenda in the release of the Medicare physician reimbursement data. <i>Urology</i> , 2014 , 84, 501-26	1	
257	Re: Introduction of Surgical Safety Checklists in Ontario, Canada. <i>Journal of Urology</i> , 2014 , 192, 1146-1147	5	
256	The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer. <i>Urology Practice</i> , 2014 , 1, 127-133	0.8	1
255	The Impact of Gender on Use of Pelvic Lymphadenectomy at the Time of Radical Cystectomy. <i>Urology Practice</i> , 2014 , 1, 146-150	0.8	
254	Re: Physicians' Attitudes about Multiplex Tumor Genomic Testing. <i>Journal of Urology</i> , 2014 , 192, 1422-1423	3	
253	Epidemiology of vocal fold paralyses after total thyroidectomy for well-differentiated thyroid cancer in a Medicare population. <i>Otolaryngology - Head and Neck Surgery</i> , 2014 , 150, 548-57	5.5	59
252	Re: urologists' use of intensity-modulated radiation therapy for prostate cancer. <i>Journal of Urology</i> , 2014 , 191, 1292	2.5	2
251	Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. <i>Urology</i> , 2014 , 83, 1309-15	1.6	25
250	Re: public financing of the Medicare program will make its uniform structure increasingly costly to sustain. <i>Journal of Urology</i> , 2014 , 191, 436-7	2.5	
249	Re: surgical skill and complication rates after bariatric surgery. <i>Journal of Urology</i> , 2014 , 191, 437-8	2.5	
248	Re: Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. <i>Journal of Urology</i> , 2014 , 192, 422-3	2.5	
247	Re: variation in surgical-readmission rates and quality of hospital care. <i>Journal of Urology</i> , 2014 , 191, 1363-4	2.5	1
246	Re: use of statins and the risk of death in patients with prostate cancer. <i>Journal of Urology</i> , 2014 , 191, 1288-9	2.5	
245	Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. <i>American Journal of Medicine</i> , 2014 , 127, 633-640.e11	2.4	31
244	Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. <i>Journal of Urology</i> , 2014 , 192, 1360-4	2.5	12

243	Knowledge of the harms of tobacco use among patients with bladder cancer. <i>Cancer</i> , 2014 , 120, 3914-226.4	24
242	Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. <i>BJU International</i> , 2014 , 113, 894-9	5.6 48
241	Racial variation in the quality of surgical care for bladder cancer. <i>Cancer</i> , 2014 , 120, 1018-25	6.4 34
240	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. <i>Cancer</i> , 2014 , 120, 1263-71	6.4 33
239	Trends in the use of evidence-based therapy for resectable gastric cancer. <i>Journal of Surgical Oncology</i> , 2014 , 110, 285-90	2.8 23
238	The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , 2014 , 110, 227-32	2.8 60
237	Response. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt466	9.7
236	The more, the merrier: including a medical oncologist in treatment planning for localized prostate cancer. <i>Journal of Oncology Practice</i> , 2014 , 10, 113-4	3.1 1
235	Assessment of patient experience with unilateral vocal fold immobility: a preliminary study. <i>Journal of Voice</i> , 2014 , 28, 636-43	1.9 30
234	Re: variation among primary care physicians in prostate-specific antigen screening of older men. <i>Journal of Urology</i> , 2014 , 191, 1291-2	2.5
233	Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. <i>Journal of the American College of Surgeons</i> , 2014 , 218, 66-72	4.4 6
232	The politics of prostate cancer screening. <i>Urologic Clinics of North America</i> , 2014 , 41, 249-55	2.9 10
231	Learning to see the forest through the trees. <i>Surgery</i> , 2014 , 155, 797-8	3.6
230	Re: value-based insurance design: quality improvement but no cost savings. <i>Journal of Urology</i> , 2014 , 191, 761-2	2.5
229	Re: association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. <i>Journal of Urology</i> , 2014 , 192, 177-8	2.5 1
228	Re: Surgical site infections following ambulatory surgery procedures. <i>Journal of Urology</i> , 2014 , 192, 431-2.5	
227	Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6583-6583	2.2
226	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5040-5040	2.2

225	Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 31-31	2.2	
224	Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. <i>Journal of Urology</i> , 2013 , 189, 2109-10	2.5	
223	Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. <i>Journal of General Internal Medicine</i> , 2013 , 28, 1494	4	
222	Early detection of prostate cancer: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 419-26	2.5	721
221	Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. <i>Urology</i> , 2013 , 82, 327-33	1.6	26
220	Re: Explaining racial differences in prostate cancer mortality. <i>Journal of Urology</i> , 2013 , 189, 2109	2.5	
219	Trends in the multimodality treatment of resectable colorectal liver metastases: an underutilized strategy. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 1938-46	3.3	9
218	Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. <i>Supportive Care in Cancer</i> , 2013 , 21, 3461-9	3.9	26
217	ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. <i>European Urology</i> , 2013 , 63, 67-80	10.2	180
216	Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). <i>BJU International</i> , 2013 , 111, 213-20	5.6	28
215	Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. <i>Journal of Urology</i> , 2013 , 189, 1782-8	2.5	69
214	Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. <i>Urology</i> , 2013 , 82, 410-5	1.6	12
213	Centralization of radical prostatectomy in the United States. <i>Journal of Urology</i> , 2013 , 189, 500-6	2.5	26
212	Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter?. <i>Journal of Urology</i> , 2013 , 189, 541-7	2.5	85
211	Re: Decision aids: when 'nudging' patients to make a particular choice is more ethical than balanced, nondirective content. <i>Journal of Urology</i> , 2013 , 190, 1251	2.5	
210	Re: Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. <i>Journal of Urology</i> , 2013 , 190, 902	2.5	
209	Re: Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Urology</i> , 2013 , 190, 988-9	2.5	
208	Re: a simulation shows limited savings from meeting quality targets under the medicare shared savings program. <i>Journal of Urology</i> , 2013 , 189, 1481-2	2.5	

207	Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. <i>Journal of Urology</i> , 2013 , 189, 507-13	2.5	51
206	Re: Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. <i>Journal of Urology</i> , 2013 , 190, 977	2.5	
205	Re: Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. <i>Journal of Urology</i> , 2013 , 189, 2108	2.5	
204	Re: fee-for-service will remain a feature of major payment reforms, requiring more changes in medicare physician payment. <i>Journal of Urology</i> , 2013 , 189, 1482-3	2.5	
203	Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. <i>Journal of Urology</i> , 2013 , 189, 2039-46	2.5	150
202	Re: Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. <i>Journal of Urology</i> , 2013 , 190, 2211	2.5	1
201	Re: Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. <i>Journal of Urology</i> , 2013 , 190, 1250-1	2.5	
200	The Patient Protection and Affordable Care Act: the impact on urologic cancer care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 980-4	2.8	11
199	Patterns and predictors of urodynamics use in the United States. <i>Journal of Urology</i> , 2013 , 189, 1791-6	2.5	15
198	Re: Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. <i>Journal of Urology</i> , 2013 , 190, 1766	2.5	
197	Castration-resistant prostate cancer: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 429-38	2.5	174
196	Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. <i>Cancer</i> , 2013 , 119, 2223-9	6.4	32
195	Re: Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. <i>Journal of Urology</i> , 2013 , 189, 125-6	2.5	
194	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 871-7	2.8	80
193	Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. <i>Neurourology and Urodynamics</i> , 2013 , 32, 330-5	2.3	27
192	Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 445-60	2.1	42
191	Comparative effectiveness research in localized prostate cancer treatment. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 583-93	2.1	8
190	Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 711-8	9.7	74

189	Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. <i>Pediatrics</i> , 2013 , 131, e1897-907	7.4	46
188	Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. <i>Annals of Internal Medicine</i> , 2013 , 158, 709-17	8	112
187	Accountable care organizations in surgery: location, location, location: Comment on "will accountable care organizations cut costs and improve quality for inpatient surgery?". <i>JAMA Surgery</i> , 2013 , 148, 554	5.4	
186	Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. <i>Journal of Sexual Medicine</i> , 2013 , 10, 3135-43	1.1	28
185	Long-term functional outcomes after treatment for localized prostate cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 436-45	59.2	639
184	Functional outcomes after treatment for prostate cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 1654	59.2	6
183	Vasculogenic Erectile Dysfunction 2013 , 341-348		2
182	Magnetic resonance imaging for locating nonpalpable undescended testicles: a meta-analysis. <i>Pediatrics</i> , 2013 , 131, e1908-16	7.4	29
181	Effect of age, tumor risk, and comorbidity in a u.s. Population-based cohort of men with prostate cancer. <i>Annals of Internal Medicine</i> , 2013 , 159, 370	8	4
180	A Modest Proposal: Prostate Biopsies and In-house Pathology Laboratories. <i>Reviews in Urology</i> , 2013 , 15, 135-6	1	
179	Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 39-39	2.2	
178	Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 106-106	2.2	
177	Sensitivity of Medicare claims to identify recurrence.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6522-6522	2.2	
176	Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4540-4540	2.2	
175	Obesity, body composition, and prostate cancer. <i>BMC Cancer</i> , 2012 , 12, 23	4.8	42
174	Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: a cost-minimization analysis. <i>Journal of Surgical Research</i> , 2012 , 176, e89-94	2.5	5
173	The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. <i>Journal of Urology</i> , 2012 , 187, 97-102	2.5	38
172	National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. <i>Journal of Urology</i> , 2012 , 187, 816-21	2.5	97

171	Quality of life with advanced metastatic prostate cancer. <i>Urologic Clinics of North America</i> , 2012 , 39, 505-515	1.5	19
170	Volume outcomes of cystectomy--is it the surgeon or the setting?. <i>Journal of Urology</i> , 2012 , 188, 2139-44	4.5	43
169	Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer. <i>Urology</i> , 2012 , 79, 1034-41	1.6	8
168	Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. <i>Urology</i> , 2012 , 80, 77-83	1.6	49
167	Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. <i>Urology</i> , 2012 , 80, 632-40	1.6	38
166	Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, S2-4	2.8	1
165	Racial variation in the quality of surgical care for prostate cancer. <i>Journal of Urology</i> , 2012 , 188, 1279-85	2.5	23
164	Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. <i>Value in Health</i> , 2012 , 15, 716-23	3.3	8
163	Trends in Care Delivery for Disorders of the Female Pelvic Floor. <i>Current Bladder Dysfunction Reports</i> , 2012 , 7, 194-200	0.4	
162	The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. <i>Cancer</i> , 2012 , 118, 5652-62	6.4	27
161	The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. <i>Cancer</i> , 2012 , 118, 5955-63	6.4	100
160	Epidemiology and cost of ventral hernia repair: making the case for hernia research. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2012 , 16, 179-83	3.2	561
159	Factors influencing patients' acceptance and adherence to active surveillance. <i>Journal of the National Cancer Institute Monographs</i> , 2012 , 2012, 207-12	4.8	29
158	Adhering to the standard of care for prostate cancer. <i>Health Affairs</i> , 2012 , 31, 1367; author reply 1367	7	1
157	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. <i>Canadian Urological Association Journal</i> , 2012 , 6, 83-8	1.2	5
156	Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. <i>Health Affairs</i> , 2012 , 31, 730-40	7	31
155	Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. <i>Journal of Urology</i> , 2011 , 185, 1828-34	2.5	62
154	Choledocholithiasis management in rural America: health disparity or health opportunity?. <i>Journal of Surgical Research</i> , 2011 , 170, 214-9	2.5	10

153	Re: The Practice of Imaging Self-Referral Doesn't Produce Much One-Stop Service. <i>Journal of Urology</i> , 2011 , 185, 2288-2288	2.5	
152	Update on AUA guideline on the management of benign prostatic hyperplasia. <i>Journal of Urology</i> , 2011 , 185, 1793-803	2.5	786
151	Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. <i>Journal of Urology</i> , 2011 , 185, 2102-7	2.5	73
150	Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. <i>Journal of Urology</i> , 2011 , 186, 829-34	2.5	78
149	Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. <i>Journal of Urology</i> , 2011 , 186, 2316-22	2.5	48
148	Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. <i>Journal of Urology</i> , 2011 , 186, 2221-7	2.5	45
147	Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. <i>International Journal of General Medicine</i> , 2011 , 4, 481-6	2.3	10
146	The association between diffusion of the surgical robot and radical prostatectomy rates. <i>Medical Care</i> , 2011 , 49, 333-9	3.1	68
145	Trends in the treatment of localized prostate cancer using supplemented cancer registry data. <i>BJU International</i> , 2011 , 107, 576-84	5.6	70
144	Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. <i>BJU International</i> , 2011 , 107, 1223-31	5.6	19
143	Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. <i>BJU International</i> , 2011 , 108, 851-6; discussion 856-7	5.6	35
142	Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. <i>BJU International</i> , 2011 , 108, 660-4	5.6	19
141	Pelvic organ prolapse (POP) surgery: the evidence for the repairs. <i>BJU International</i> , 2011 , 107, 1704-19	5.6	29
140	Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. <i>World Journal of Urology</i> , 2011 , 29, 3-9	4	34
139	Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. <i>World Journal of Urology</i> , 2011 , 29, 51-7	4	26
138	Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. <i>Journal of General Internal Medicine</i> , 2011 , 26, 1305-10	4	27
137	Epidemiology of stress urinary incontinence in women. <i>Current Urology Reports</i> , 2011 , 12, 370-6	2.9	72
136	Re: Acquisition of MRI Equipment by Doctors Drives up Imaging Use and Spending. <i>Journal of Urology</i> , 2011 , 185, 2289-2290	2.5	

135	Quality of life after breast cancer diagnosis and survival. <i>Journal of Clinical Oncology</i> , 2011 , 29, 406-12	2.2	105
134	Treatment for postprostatectomy incontinence: is this as good as it gets?. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 197-8	27.4	1
133	Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. <i>American Journal of Nephrology</i> , 2011 , 34, 64-70	4.6	6
132	What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 740-50	4	37
131	Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. <i>BJU International</i> , 2010 , 106, 322-8	5.6	33
130	Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1069-74	2.2	79
129	Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1780-93	9.7	114
128	Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. <i>Journal of Urology</i> , 2010 , 183, 1504-9	2.5	29
127	Urology Board ReviewLeslieS.W.: Urology Board Review. New York: McGraw Hill Medical2009. 521 pages.. <i>Journal of Urology</i> , 2010 , 183, 2473-2473	2.5	
126	755 URINARY FUNCTION EVALUATION IN FEMALE CYSTECTOMY PATIENTS WITH ORTHOTOPIC DIVERSION UTILISING A VALIDATED HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE. <i>Journal of Urology</i> , 2010 , 183,	2.5	3
125	Health related quality of life for men treated for localized prostate cancer with long-term followup. <i>Journal of Urology</i> , 2010 , 183, 2206-12	2.5	101
124	Socioeconomic factors, urological epidemiology and practice patterns. <i>Journal of Urology</i> , 2010 , 184, 1991-4	2.5	1
123	Health care reform 2010: a fresh view on tort reform. <i>Journal of Urology</i> , 2010 , 184, 1840-6	2.5	9
122	Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. <i>Journal of Urology</i> , 2010 , 184, 120-5	2.5	9
121	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 411-22	59.2	3838
120	Clinical Trials in Urology 2010 , 12-17		
119	Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 381-6	2.7	5
118	Preliminary treatment considerations among men with newly diagnosed prostate cancer. <i>American Journal of Managed Care</i> , 2010 , 16, e121-30	2.1	37

117	Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. <i>Journal of Sexual Medicine</i> , 2009 , 6, 1969-78	1.1	27
116	Access to information sources and treatment considerations among men with local stage prostate cancer. <i>Urology</i> , 2009 , 74, 509-15	1.6	25
115	Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 466-72	2.8	27
114	Treatment of a population based sample of men diagnosed with testicular cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 604-10	2.8	21
113	Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. <i>Journal of Urology</i> , 2009 , 181, 2214-21; discussion 2221-2	2.5	49
112	Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. <i>Journal of Urology</i> , 2009 , 181, 2052-8; discussion 2058-9	2.5	70
111	Erectile aid use by men treated for localized prostate cancer. <i>Journal of Urology</i> , 2009 , 182, 649-54	2.5	28
110	Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. <i>Journal of Urology</i> , 2009 , 182, 2182-7	2.5	53
109	The Impact of Prostate Cancer Diagnosis and Post-treatment Sexual Dysfunction on Quality of Life 2009 , 17-32		1
108	Active surveillance: not your father's watchful waiting. <i>Oncology</i> , 2009 , 23, 980, 982	1.8	3
107	Invasive T1 bladder cancer: indications and rationale for radical cystectomy. <i>BJU International</i> , 2008 , 102, 270-5	5.6	35
106	Evaluating localized prostate cancer and identifying candidates for focal therapy. <i>Urology</i> , 2008 , 72, S12-24		101
105	Prostate cancer: epidemiology and health-related quality of life. <i>Urology</i> , 2008 , 72, S3-11	1.6	26
104	Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 564-565	2.8	1
103	Quality of life and satisfaction with outcome among prostate-cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 565-566	2.8	1
102	Health-related quality of life results in pathologic Stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 567-568	2.8	1
101	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008 , 19, 175-81	2.8	275
100	Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. <i>Journal of Urology</i> , 2008 , 180, 520-4; discussion 524	2.5	33

99	5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. <i>Journal of Urology</i> , 2008 , 179, S40-4	2.5	102
98	Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. <i>Patient</i> , 2008 , 1, 189	3.7	5
97	Internet health resources and the cancer patient. <i>Cancer Investigation</i> , 2008 , 26, 202-7	2.1	70
96	Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. <i>Medical Decision Making</i> , 2008 , 28, 323-31	2.5	80
95	Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>American Journal of Epidemiology</i> , 2008 , 167, 925-34	3.8	135
94	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 224-9	12.9	54
93	Assessing the quality of prostate cancer care. <i>Current Opinion in Urology</i> , 2008 , 18, 297-302	2.8	9
92	The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. <i>Current Urology Reports</i> , 2008 , 9, 179-81	2.9	4
91	Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008 , 68, 1477-86	4.2	48
90	13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. <i>Journal of Urology</i> , 2007 , 177, 932-6	2.5	107
89	Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. <i>Journal of Urology</i> , 2007 , 178, 756-60	2.5	61
88	On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 1992-9	2.5	46
87	Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 876-81; discussion 881-2	2.5	117
86	Pay for performance: rationale and potential implications for urology. <i>Journal of Urology</i> , 2007 , 178, 402-8	2.5	13
85	Prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 2020-9	2.5	59
84	Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. <i>Journal of Urology</i> , 2007 , 177, 1307-12	2.5	15
83	Quality of life after therapy for localized prostate cancer. <i>Cancer Journal (Sudbury, Mass.)</i> , 2007 , 13, 318-26	2.5	28
82	Trends in treatment costs for localized prostate cancer: the healthy screenee effect. <i>Medical Care</i> , 2007 , 45, 154-9	3.1	43

81	Survival associated with treatment vs. observation of localized prostate cancer in elderly men: Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K, Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 440-441	2.8	
80	On the importance of race, socioeconomic status, and comorbidity when evaluating quality of life in men with prostate cancer: Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF, Fred Hutchinson Cancer Research Center, Seattle, WA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 442-443	2.8	
79	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer: Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE, Department of Urology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 442-443	2.8	1
78	Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , 2007 , 177, 1395-400; quiz 1591	2.5	169
77	Pharmacoeconomics of available treatment options for metastatic prostate cancer. <i>Pharmacoeconomics</i> , 2007 , 25, 309-27	4.4	6
76	Ethical Issues in Clinical Research 2006 , 31-46		
75	Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. <i>Journal of Sexual Medicine</i> , 2006 , 3, 1059-1067	1.1	54
74	Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. <i>Journal of Sexual Medicine</i> , 2006 , 3, 1068-1076	1.1	20
73	Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. <i>Cancer</i> , 2006 , 106, 1865-74	6.4	211
72	Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. <i>Nature Reviews Urology</i> , 2006 , 3, 449-52		1
71	Prostate cancer on the Internet--information or misinformation?. <i>Journal of Urology</i> , 2006 , 175, 1836-42; discussion 1842	2.5	56
70	Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. <i>Journal of Urology</i> , 2006 , 176, 2025-31; discussion 2031-2	2.5	111
69	Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. <i>Urology</i> , 2006 , 68, 80-4	1.6	2
68	Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. <i>Urology</i> , 2006 , 68, 1242-7	1.6	17
67	The effectiveness of screening for prostate cancer: a nested case-control study. <i>Archives of Internal Medicine</i> , 2006 , 166, 38-43		73
66	Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other?. <i>BJU International</i> , 2006 , 98, 105-9; discussion 109	5.6	16
65	Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 395-402	4	28
64	Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , 2005 , 174, 877-81	2.5	82

63	The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. <i>Journal of Urology</i> , 2005 , 174, 547-52; discussion 552	2.5	27
62	The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. <i>Journal of Urology</i> , 2005 , 173, 903-7	2.5	24
61	Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. <i>Urologic Clinics of North America</i> , 2005 , 32, 207-16	2.9	38
60	Prostate cancer and the Will Rogers phenomenon. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1248-53	2.5	322
59	Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?. <i>Urology</i> , 2005 , 66, 835-9	1.6	14
58	Quality of life in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 208-15	2.8	19
57	An update on randomized clinical trials in localized and locoregional prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 280-8	2.8	14
56	Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. <i>American Journal of Medicine</i> , 2005 , 118, 850-7	2.4	58
55	5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. <i>Journal of Urology</i> , 2005 , 173, 1701-5	2.5	352
54	Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. <i>Journal of Urology</i> , 2005 , 173, 1318-22	2.5	179
53	Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7783-4	2.2	5
52	Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1358-67	9.7	493
51	Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4193-201	2.2	59
50	An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. <i>American Journal of Epidemiology</i> , 2004 , 160, 1059-69	3.8	32
49	Differences in health-related quality of life of prostate cancer patients based on stage of cancer. <i>Psycho-Oncology</i> , 2004 , 13, 800-7	3.9	50
48	Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. <i>Cancer</i> , 2004 , 101, 2011-9	6.4	60
47	Laparoscopic partial nephrectomy and prostatectomy: weighing the costs and the benefits. <i>Journal of Urology</i> , 2004 , 172, 6-7	2.5	154
46	Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. <i>Journal of Urology</i> , 2004 , 171, 2221-5	2.5	68

45	The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. <i>Journal of Urology</i> , 2004 , 171, 2250-4	2.5	28
44	Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. <i>Urology</i> , 2004 , 64, 201-11	1.6	14
43	Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. <i>Urology</i> , 2004 , 64, 1171-6	1.6	84
42	Combining longitudinal studies of PSA. <i>Biostatistics</i> , 2004 , 5, 483-500	3.7	12
41	Quality-of-Life Issues in Incontinence 2004 , 53-64		
40	Quality of life after treatment for prostate cancer. <i>Current Prostate Reports</i> , 2003 , 1, 55-65		0
39	Quality of life after treatment for prostate cancer. <i>Current Urology Reports</i> , 2003 , 4, 185-95	2.9	52
38	Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. <i>Cancer</i> , 2003 , 98, 496-503	6.4	16
37	Health related quality of life in men with prostate cancer. <i>Journal of Urology</i> , 2003 , 169, 1653-61	2.5	142
36	Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. <i>Journal of Urology</i> , 2003 , 170, 905-8	2.5	34
35	The physical burden of prostate cancer. <i>Urologic Clinics of North America</i> , 2003 , 30, 305-13	2.9	29
34	Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. <i>Journal of Urology</i> , 2003 , 169, 1437-42	2.5	56
33	Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. <i>Journal of Urology</i> , 2003 , 169, 1458-61	2.5	40
32	General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1147-54	2.2	147
31	Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. <i>Diabetes Care</i> , 2003 , 26, 1093-9	14.6	164
30	Male Sexual Function: A Guide to Clinical Management. <i>Annals of Internal Medicine</i> , 2002 , 137, 300	8	1
29	Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. <i>Surgical Oncology</i> , 2002 , 11, 3-11	2.5	16
28	Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 981-90	9.7	658

27	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. <i>Journal of Urology</i> , 2002 , 168, 2490-2494	2.5	40
26	The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical results. <i>Telemedicine Journal and E-Health</i> , 2002 , 8, 123-30	5.9	18
25	Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. <i>Urology</i> , 2002 , 60, 959-636	3	31
24	Psychological Impact of Erectile Dysfunction: Validation of a New Health Related Quality of Life Measure for Patients With Erectile Dysfunction. <i>Journal of Urology</i> , 2002 , 168, 2086-2091	2.5	68
23	How Well Does The Partin Nomogram Predict Pathological Stage After Radical Prostatectomy In A Community Based Population? Results Of The Cancer Of The Prostate Strategic Urological Research Endeavor. <i>Journal of Urology</i> , 2002 , 167, 1653-1658	2.5	49
22	Racial Variation in the Incidence of Squamous Cell Carcinoma of the Bladder in the United States. <i>Journal of Urology</i> , 2002 , 168, 1960-1963	2.5	16
21	Treatment outcomes in localized prostate cancer: a patient-oriented approach. <i>Urologic Oncology</i> , 2002 , 20, 63-73		10
20	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. <i>Journal of Urology</i> , 2002 , 2490-2494		1
19	How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. <i>Journal of Urology</i> , 2002 , 167, 1653-7; discussion 1657-8	2.5	8
18	The cost-effectiveness of treatment for varicocele related infertility. <i>Journal of Urology</i> , 2002 , 168, 2490-2494	2.5	16
17	Men's health. <i>Journal of General Internal Medicine</i> , 2001 , 16, 717-718	4	
16	Men's health: are we missing the big picture?. <i>Journal of General Internal Medicine</i> , 2001 , 16, 717-8	4	4
15	Determining cause of death in prostate cancer: are death certificates valid?. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1822-3	9.7	110
14	The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. <i>Journal of Clinical Epidemiology</i> , 2001 , 54, 350-8	5.7	133
13	Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. <i>Urology</i> , 2001 , 57, 499-503	1.6	28
12	HEALTH RELATED QUALITY OF LIFE DIFFERENCES BETWEEN BLACK AND WHITE MEN WITH PROSTATE CANCER: DATA FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR. <i>Journal of Urology</i> , 2001 , 166, 2281-2285	2.5	84
11	Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. <i>BJU International</i> , 2000 , 86, 782-9	5.6	96
10	Quality of life following prostate cancer treatments. <i>Current Urology Reports</i> , 2000 , 1, 71-7	2.9	6

9	Assessing Quality of Life 2000 , 183-198		1
8	DOES SITE SPECIFIC LABELING OF SEXTANT BIOPSY CORES PREDICT THE SITE OF EXTRACAPSULAR EXTENSION IN RADICAL PROSTATECTOMY SURGICAL SPECIMEN?. <i>Journal of Urology</i> , 1999 , 162, 1352-1357	2.5	44
7	Adrenal control of erectile function and nitric oxide synthase in the rat penis. <i>Endocrinology</i> , 1997 , 138, 3925-32	4.8	51
6	Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. <i>Journal of Urology</i> , 1997 , 158, 1978-82	2.5	10
5	Computer-generated graphical presentations: use of multimedia to enhance communication. <i>Urology</i> , 1997 , 49, 2-9	1.6	8
4	Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. <i>Biology of Reproduction</i> , 1996 , 55, 567-74	3.9	121
3	Segmental Testicular Infarction in the Neonate: A Case Report. <i>Journal of Urology</i> , 1995 , 153, 1992-1993	2.5	11
2	The hemodynamic pathophysiology of impotence following blunt trauma to the erect penis. <i>Journal of Urology</i> , 1992 , 148, 1171-80	2.5	84
1	Adrenal Control of Erectile Function and Nitric Oxide Synthase in the Rat Penis		11